Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Cytologically or histologically confirmed breast cancer
• * Metastatic OR locally recurrent disease
• * Unresectable disease
• * Not amenable to radiotherapy
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
• * Measurable disease must be outside irradiated areas
• ErbB2-negative disease by immunohistochemistry (negative or 1+) or fluorescent in situ hybridization (FISH)
• No known CNS metastases, even if previously treated
• Hormone receptor status not specified
• PATIENT CHARACTERISTICS:
• Female
• Menopausal status not specified
• WHO performance status 0-1
• LVEF ≥ 55%
• Hemoglobin ≥ 10.0 g/dL
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin \< 2 times upper limit of normal (ULN)
• ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
• Alkaline phosphatase (AP) ≤ 2.5 times ULN
• * AP \> 2.5 times ULN and ≤ 6 times ULN allowed if ALT ≤ 1.5 times ULN
• * AP \> 6 times ULN allowed if ALT normal
• Creatinine ≤ 1.5 times ULN
• Proteinuria \< 2+ by dipstick OR protein ≤ 1 g/24hr-urine collection
• INR ≤ 1.5 OR Quick ≥ 70%
• aPTT ≤ 1.5 times ULN
• No peripheral neuropathy \> grade 2
• No history or evidence of hereditary bleeding diathesis or coagulopathy with the risk of bleeding
• No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg and/or diastolic BP \> 100 mm Hg, measured repeatedly at \> 2 visits despite adequate treatment with ≥ 2 different antihypertensive drugs
• No clinically significant cardiovascular disease, including the following:
• * Cerebrovascular accident or stroke within the past 6 months
• * Myocardial infarction within the past 6 months
• * Unstable angina
• * New York Heart Association class II-IV congestive heart failure
• * Serious cardiac arrhythmia (e.g., ventricular arrhythmia, high-grade atrioventricular-block) not controlled by medication or requiring medication which might interfere with regularity of the study treatment
• No serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or bleeding skin metastases
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No active infection requiring IV antibiotics
• No known hypersensitivity to any of the study drugs or excipients
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• No evidence of any other disease that contraindicates the use of an investigational drug, that may affect patient compliance with study routines, or places the patient at high risk for treatment-related complications including, but not limited to, the following:
• * Metabolic dysfunction
• * Physical examination finding
• * Psychological dysfunction
• * Clinical laboratory finding giving reasonable suspicion of a disease or condition
• No known CNS disease unrelated to cancer (e.g., uncontrolled seizures), unless adequately treated with standard medical therapy
• No high-risk factors for bleeding, including the following:
• * Coagulation parameters outside range
• * Need for concurrent anticoagulant therapy
• * Insufficient time gap after surgical procedures
• No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
• No significant traumatic injury within the past 28 days
• No known HIV positivity
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 12 months after completion of study therapy
• PRIOR CONCURRENT THERAPY:
• No prior chemotherapy for metastatic or inoperable locally recurrent breast cancer
• No prior bevacizumab or other anti-vascular endothelial growth factor drug therapy
• No prior radiotherapy involving the heart (usual irradiation dose to breast or chest wall allowed)
• More than 12 months since prior neoadjuvant or adjuvant chemotherapy
• No neoadjuvant or adjuvant doxorubicin hydrochloride with cumulative dose \> 360 mg/m² or epirubicin hydrochloride with cumulative dose \> 720 mg/m²
• More than 6 months since prior adjuvant radiotherapy
• More than 28 days since prior major surgical procedure with high risk of bleeding
• More than 24 hours since prior minor surgical procedures
• More than 10 days since prior acetylsalicylic acid (\> 325 mg/day) or clopidogrel bisulfate (\> 75 mg/day)
• More than 10 days since prior and no concurrent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes
• * Prophylactic use of anticoagulants allowed (e.g., for maintenance of venous catheter)
• More than 30 days since prior investigational therapies or participation in other investigational studies
• No concurrent hormonal therapy
• No other concurrent antineoplastic or antitumor therapy
• No other concurrent investigational drugs
• No concurrent radiotherapy
• No concurrent nonsteroidal anti-inflammatory drugs with activity on platelets and gastric mucosa (e.g., dipyridamole, clopidogrel bisulfate, acetylsalicylic acid)
• No anticipated need for major surgery during the course of the study treatment